Cellgram-LC(Cellgram-LC) - _专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

Autologous bone marrow-derived mesenchymal stem cell(Pharmicell)

靶点-

作用方式-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Pharmicell Co., Ltd.

在研机构

Pharmicell Co., Ltd.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Cellgram-LC 相关的临床试验

JPRN-jRCT2063210037

/ Completed临床1/2期IIT

Investigator-initiated Clinical Trial to Evaluate the Safety and Efficacy of Magnetic targeting using Autologous Bone Marrow-derived Mesenchymal Stem Cell (m-MSC) in Knee Osteoarthritis

开始日期2021-10-20

申办/合作机构-

NCT05093881

/ RecruitingN/A

Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study

This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

开始日期2021-08-24

申办/合作机构

Pharmicell Co., Ltd.

NCT04689152

/ Recruiting临床3期

A Multicenter, Randomized, Open-label Phase III Clinical Trial to Evaluate Efficacy and Safety of the Cellgram-LC in Patients With Alcoholic Liver Cirrhosis

This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.

开始日期2021-03-02

申办/合作机构

Pharmicell Co., Ltd.

100 项与 Cellgram-LC 相关的临床结果

登录后查看更多信息

100 项与 Cellgram-LC 相关的转化医学

登录后查看更多信息

100 项与 Cellgram-LC 相关的专利（医药）

登录后查看更多信息

100 项与 Cellgram-LC 相关的药物交易

登录后查看更多信息